TWI818948B - 啉酮衍生物 - Google Patents

啉酮衍生物 Download PDF

Info

Publication number
TWI818948B
TWI818948B TW108101951A TW108101951A TWI818948B TW I818948 B TWI818948 B TW I818948B TW 108101951 A TW108101951 A TW 108101951A TW 108101951 A TW108101951 A TW 108101951A TW I818948 B TWI818948 B TW I818948B
Authority
TW
Taiwan
Prior art keywords
group
compound
salt
alkoxy
alkyl
Prior art date
Application number
TW108101951A
Other languages
English (en)
Chinese (zh)
Other versions
TW201938156A (zh
Inventor
木方俊宏
矢野辰也
小森谷聰
田中太作
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW201938156A publication Critical patent/TW201938156A/zh
Application granted granted Critical
Publication of TWI818948B publication Critical patent/TWI818948B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108101951A 2018-01-18 2019-01-18 啉酮衍生物 TWI818948B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-006269 2018-01-18
JP2018006269 2018-01-18

Publications (2)

Publication Number Publication Date
TW201938156A TW201938156A (zh) 2019-10-01
TWI818948B true TWI818948B (zh) 2023-10-21

Family

ID=67302218

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108101951A TWI818948B (zh) 2018-01-18 2019-01-18 啉酮衍生物

Country Status (12)

Country Link
US (1) US11530211B2 (https=)
EP (1) EP3741757B1 (https=)
JP (1) JP7359697B2 (https=)
KR (1) KR20200110338A (https=)
CN (1) CN111630052B (https=)
AU (1) AU2019208634B2 (https=)
CA (1) CA3088968C (https=)
ES (1) ES2958118T3 (https=)
IL (1) IL276125A (https=)
SG (1) SG11202006837XA (https=)
TW (1) TWI818948B (https=)
WO (1) WO2019142883A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040966A (zh) * 2019-07-08 2022-02-11 国立大学法人东京工业大学 使用了二氢吲嗪酮衍生物的胰岛素生产细胞的制作法
EP4727939A1 (en) * 2023-06-14 2026-04-22 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504782A (ja) * 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
WO2010077686A1 (en) * 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
JP2011518563A (ja) * 2008-04-24 2011-06-30 セントコア・オーソ・バイオテツク・インコーポレーテツド 多能性細胞の処理
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
JP2017522347A (ja) * 2014-07-31 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2012056997A1 (ja) 2010-10-28 2012-05-03 国立大学法人熊本大学 多能性幹細胞の分化誘導効率を改善するための方法及び培地
AU2013255031C1 (en) 2012-04-30 2018-12-06 University Health Network Methods and compositions for generating pancreatic progenitors and functional beta cells from hPSCs
JP2014161257A (ja) 2013-02-22 2014-09-08 Univ Of Tokyo 多能性幹細胞から膵ランゲルハンス島を製造する方法
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
DK3039122T3 (da) 2013-08-30 2019-09-30 Novo Nordisk As Generering af endokrine progenitorceller fra humane pluripotente stamceller under anvendelse af små molekyler
WO2015125662A1 (ja) 2014-02-21 2015-08-27 国立大学法人熊本大学 アミノ酸組成変更培地を用いた幹細胞の分化促進方法、及び該方法を用いて処理された幹細胞、並びに培地
JP6094516B2 (ja) 2014-03-19 2017-03-15 三菱電機株式会社 エレベーター装置
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10457916B2 (en) 2014-05-20 2019-10-29 Tokyo Institute Of Technology Method for inducing differentiation of insulin-producing cells
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US20160177268A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating augmented stem cell-derived beta cells and uses thereof
CA2979293C (en) 2015-03-11 2022-01-04 Timothy J. Kieffer Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504782A (ja) * 2005-08-18 2009-02-05 アルナイラム ファーマシューティカルズ インコーポレイテッド 神経疾患を治療するための方法および組成物
JP2011518563A (ja) * 2008-04-24 2011-06-30 セントコア・オーソ・バイオテツク・インコーポレーテツド 多能性細胞の処理
WO2010077686A1 (en) * 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
JP2017522347A (ja) * 2014-07-31 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体

Also Published As

Publication number Publication date
AU2019208634A1 (en) 2020-08-06
EP3741757A4 (en) 2021-11-03
CN111630052B (zh) 2023-04-18
CA3088968A1 (en) 2019-07-25
TW201938156A (zh) 2019-10-01
CA3088968C (en) 2023-10-17
EP3741757B1 (en) 2023-07-26
AU2019208634A2 (en) 2020-09-24
US20210053965A1 (en) 2021-02-25
CN111630052A (zh) 2020-09-04
IL276125A (en) 2020-08-31
AU2019208634B2 (en) 2024-06-13
SG11202006837XA (en) 2020-08-28
JPWO2019142883A1 (ja) 2021-01-14
US11530211B2 (en) 2022-12-20
JP7359697B2 (ja) 2023-10-11
EP3741757A1 (en) 2020-11-25
ES2958118T3 (es) 2024-02-01
WO2019142883A1 (ja) 2019-07-25
KR20200110338A (ko) 2020-09-23

Similar Documents

Publication Publication Date Title
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
CA2723233C (en) Specific inhibitors for vascular endothelial growth factor receptors
KR102575246B1 (ko) 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
TW200800181A (en) Pharmaceutical composition for anticancer
CN102844023A (zh) Cdc7激酶抑制剂以及其用途
CN107531683B (zh) Usp7抑制剂化合物及使用方法
JP2016539180A (ja) １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体
TWI818948B (zh) 啉酮衍生物
US20200078319A1 (en) Pharmaceutical composition, containing nm23 activator, for inhibiting cancer metastasis
CN108299420A (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用
CN110114353B (zh) 苯并[b]噻吩酰胺类衍生物及其用途
TWI858093B (zh) 使用二氫吲哚啉酮衍生物之胰島素產生細胞之製作方法
JP2021521179A (ja) Ｖｐｓ３４の阻害剤としてのモルホリン誘導体
HK40031650A (en) Dihydroindolizinone derivative
HK40031650B (en) Dihydroindolizinone derivative
HK40066575A (en) Method for producing insulin-producing cell using dihydroindolizinone derivatives
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
WO2024020170A1 (en) Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
HK40079392A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2016135140A1 (en) 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
CN121712769A (zh) 新型硒吩衍生物